SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wilczak, N
Right arrow Articles by De Keyser, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilczak, N
Right arrow Articles by De Keyser, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis

N Wilczak

Department of Neurology, University Hospital Groningen, Groningen, The Netherlands

G SM Ramsaransing

Department of Neurology, University Hospital Groningen, Groningen, The Netherlands

J Mostert

Department of Neurology, University Hospital Groningen, Groningen, The Netherlands

D Chesik

Department of Neurology, University Hospital Groningen, Groningen, The Netherlands

J De Keyser

Department of Neurology, University Hospital Groningen, Groningen, The Netherlands, j.h.a.de.keyser{at}neuro.azg.nl

Using radioimmunoassay we measured serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 in patients with relapsing multiple sclerosis (MS) and a benign course (Expanded Disability Status Scale (EDSS)≤ 3 despite > 10 years disease duration), relapsing MS with cumulative disability leading to an EDSS score > 4 within 10 years of disease duration, primary progressive MS and healthy controls. We found no differences in IGF-1 and IGFBP-3 serum levels, and the IGF-1/IGFBP-3 ratio between the four groups. However, there was a significant correlation (P=0.005) between IGFBP-3 serum levels and both the progression index of disability and the Multiple Sclerosis Severity Score in patients with primary progressive MS.

Key Words: disease progression • insulin-like growth factor • insulin-like growth factor binding protein-3 • multiple sclerosis • primary progressive MS

Multiple Sclerosis, Vol. 11, No. 1, 13-15 (2005)
DOI: 10.1191/1352458505ms1123oa
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement